Portal de Periódicos da CAPES

Artigo Produção Nacional Revisado por pares

BIBTEX RIS

Thalidomide and Analogs as Anti-Inflammatory and Immunomodulator Drug Candidates

2006; Bentham Science Publishers; Volume: 5; Issue: 1 Linguagem: Inglês

10.2174/187152306775537328

1875-614X

Lı́dia Moreira Lima, Carlos Alberto Manssour Fraga, Vera Lúcia Gonçalves Koatz, Eliezer J. Barreiro,

Cancer therapeutics and mechanisms

Thalidomide ([2-(2,6-dioxo-hexahydro-3-(R,S)-pyridinyl)-1,3-isoindolinedione]), well known by its teratogenic effect, caused birth defects in up to 12,000 children in the 1960s. More recently, this drug was approved by the US Food and Drug Administration for the treatment of erythema nodosum leprosum, under restricted-use program, and a variety of new possible therapeutic applications have been described. This article will accomplish a review of medicinal chemistry aspects of thalidomide and state of the art in the development of new anti-inflammatory and immunomodulator drug candidates designed using thalidomide as lead-compound.